ACC 2025 29 - 31 March 2025

Effect of the GLP-1 receptor agonist semaglutide on total cardiovascular events in patients with cardiovascular disease and overweight or obesity but no diabetes in the SELECT trial

Authors :

A. Michael Lincoff¹; Helen M. Colhoun²; Scott S. Emerson³; G. Kees Hovingh⁴; M. Giray Kabakci⁵; Steven E. Kahn⁶; Ildiko Lingvay⁷; Ana Laura S.A. Matos⁴; Cristobal Morales-Portillo⁸; Søren Rasmussen⁴; Jose F.K. Saraiva⁹; Benjamin M. Scirica¹⁰; Francisco J. Tinahones¹¹; Philippe Van de Borne¹²; Subodh Verma¹³; Peter E. Weeke⁴; Donna H. Ryan¹⁴; John Deanfield¹⁵

Affiliations

View Details Hide Details

Keywords

Obesity

Cardiovascular Disease

Congress poster

GLP-1 RA

Semaglutide

PHASE 3 (RCT)

Are you a healthcare professional?

Effect of the GLP-1 receptor agonist semaglutide on total cardiovascular events in patients with cardiovascular disease and overweight or obesity but no diabetes in the SELECT trial